This inventor holds 1 USPTO granted patent. Top assignee: Japan Science and Technology Agency. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: Kiyoshi Takeda: Innovator in Immunological Research
Introduction: Kiyoshi Takeda, based in Mino, Japan, is a notable inventor recognized for his significant contributions to immunology. His innovative work focuses on the development of models that elucidate the role of specific proteins in the immune response to bacterial components.
Latest Patents: Takeda holds one patent titled "Bacterial cell component-unresponsive model mouse." This patent describes a knockout mouse that is unresponsive to peptidoglycan and similar molecules. Such a model is imperative for understanding the signaling pathways activated by bacterial cell components in vivo, particularly focusing on the roles of TLR2 and MyD88. The knockout mouse is created through a meticulous process involving the construction of a targeting vector that replaces part of the TLR2 or MyD88 gene with a plasmid containing a poly A signal and marker gene, followed by microinjection into a mouse blastocyst.
Career Highlights: Takeda is affiliated with the Japan Science and Technology Agency, where he conducts pioneering research in the field of immunology. His work significantly enhances the understanding of immunological responses and the underlying mechanics of bacterial infections.
Collaborations: Throughout his career, Takeda has collaborated with esteemed researchers in the field, including Shizuo Akira and Osamu Takeuchi. These partnerships have fostered advancements in vaccine development and therapeutic strategies for infectious diseases.
Conclusion: Kiyoshi Takeda’s innovative approaches and patent contributions play a vital role in the ongoing research and understanding of immune responses. His work not only aids in the elucidation of complex biological processes but also paves the way for future therapeutic advancements in immunology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
